Observed arrival · 2026-11-06
Precedia puts regulatory precedent on the page
A free research tool for searching and browsing nonclinical evidence from FDA- and EMA-approved drugs.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Nonclinical toxicology and regulatory teams preparing drug-development packages
- Worth noticing
- Sample records cite FDA multi-discipline reviews by application number and pinpoint page, while explicitly showing gaps in the evidence.
Field notes
Visitors can browse approval records by modality and compare fields such as species, longest study, first dose, skipped studies, and risks; the page says selecting a cell opens the regulator’s sentence. Its examples cite FDA multi-discipline reviews by application number and page, including records for elranatamab, teclistamab, and tarlatamab. The site reports 771 cases of accepted departures from guideline wording and lists a planned update for 7 December 2026.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue